Alnylam Pharmaceuticals
ALNY
#591
Rank
โ‚น2.960 T
Marketcap
โ‚น22,956
Share price
-0.29%
Change (1 day)
62.05%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - P/B ratio

P/B ratio as of November 2024 : > 1000

According to Alnylam Pharmaceuticals 's latest financial reports the company has a price-to-book ratio of 16.7612.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.

Alnylam Pharmaceuticals - P/B ratio (from 2004 to 2024)

P/B ratio by year

Year P/B ratio Change
2024-12-31N/A-100%
2023-12-31-109-41.09%
2022-12-31-185-635.91%
2021-12-3134.5132.06%
2020-12-3114.965.45%
2019-12-318.9858.51%
2018-12-315.67-20.57%
2017-12-317.13104.3%
2016-12-313.49-44.88%
2015-12-316.33-20.81%
2014-12-318.00-47.24%
2013-12-3115.2112.15%
2012-12-317.15142.14%
2011-12-312.9511.85%
2010-12-312.64-36.3%
2009-12-314.14-18.25%
2008-12-315.07-14.89%
2007-12-315.9551.05%
2006-12-313.94-5.49%
2005-12-314.1733.58%
2004-12-313.12
2003-12-31N/A

P/B ratio for similar companies or competitors

Company P/B ratio P/B ratio differencediff. Country
7.84-99.28%๐Ÿ‡บ๐Ÿ‡ธ USA
3.09-99.72%๐Ÿ‡บ๐Ÿ‡ธ USA
10.7-99.02%๐Ÿ‡บ๐Ÿ‡ธ USA
0.7191-99.93%๐Ÿ‡บ๐Ÿ‡ธ USA
0.9868-99.91%๐Ÿ‡บ๐Ÿ‡ธ USA
4.93-99.55%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
1.67-99.85%๐Ÿ‡ซ๐Ÿ‡ท France
3.02-99.72%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel